Review of Microneedle Technology for Targeted Therapeutics in Vitiligo: Design Principles, Application Prospects
Yihui Yu,Wei Li,Qian Li,Wenyan Liu,Sanquan Zhang,Xibao Zhang,Jingyao Liang
DOI: https://doi.org/10.2147/dddt.s449381
IF: 4.3188
2024-11-04
Drug Design Development and Therapy
Abstract:Yihui Yu, 1 Wei Li, 1, 2 Qian Li, 1, 2 Wenyan Liu, 1, 2 Sanquan Zhang, 1, 2 Xibao Zhang, 1, 2 Jingyao Liang 1, 2 1 Institute of Dermatology, Guangzhou Medical University, Guangzhou, 510095, People's Republic of China; 2 Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, 510095, People's Republic of China Correspondence: Jingyao Liang; Xibao Zhang, Email ; Vitiligo is a chronic autoimmune disorder characterized by depigmented patches of the skin. The treatment of vitiligo remains challenging, partly owing to the lack of efficient drug delivery system. Microneedles (MNs), an ideal transdermal drug delivery system, have emerged as promising drug delivery platform for vitiligo. Recently, the emergence of novel MNs with increased biocompatibility, including hydrogel and hollow MNs, further enhance the translational value of MNs in the treatment of vitiligo. However, up-to-date review of these advancements remains lacking. This review aims to summarize the most recent studies of MN-based drug delivery systems for vitiligo, highlighting the translational potential of MNs as a therapeutic platform for the treatment of vitiligo in the near future. Keywords: vitiligo treatment, microneedle design, advanced applications Graphical Vitiligo is a dermatological condition characterized by the acquired depletion of melanocytes, which leads to the appearance of white macules in the skin. 1 The current understanding of the etiology of vitiligo is associated with the overactivation of the immune cells, specifically the activation of CXCR3 + CD8 + cytotoxic T cells. 2 Several anti-inflammatory therapeutics, including tofacitinib (JAK-STAT inhibitor) and tacrolimus (calcineurin inhibitor), have been widely used to combat vitiligo in clinical application. However, given that the CXCR3 + CD8 + T cells are mainly located in the dermal-epidermal junction, it remains challenging for the therapeutics to be effectively delivered to the targeted region. In addition, systemic medications have the potential to induce undesirable adverse effects, whereas topical ointments and creams exhibit limited permeability, subsequently reducing their clinical efficacy. As a result, there is an increasing demand for more effective and safe targeted treatments for vitiligo. Recently, microneedles (MNs) have caught significant attention as a transdermal drug delivery method. MNs are micrometer-sized needles that increase the diffusivity of the drug to the stratum corneum (SC) by creating micron-size pores in the skin. Specifically, solid MNs can reach to the dermal-epidermal junction of the skin, and was the first MNs that applied clinically to treat skin diseases, including vitiligo. Previous review that analyzed the efficacy and safety of solid MNs in treating vitiligo found that solid MNs can significantly improve vitiligo lesion without causing observable side effect, suggesting that solid MNs may serve as an alternative treatment for vitiligo for patients whose resistant to conventional therapies. 3 Recently, new types of MNs have been developed, including hollow MNs, coated MNs, dissolving MNs and hydrogel MNs, all of which further improve the bioavailability and drug delivery efficacy of MNs in skin diseases, including vitiligo. Here, we aim to summarize the latest research on MNs-based drug delivery systems for vitiligo, highlighting the translational potential of MNs as a therapeutic platform for the management of vitiligo in the near future. All the studies included in this review were searched on PubMed ( https://pubmed.ncbi.nlm.nih.gov ), Web of Science ( https://webofscience.clarivate.cn/ ) and Embase ( https://www.embase.com/ ) with keywords including the combination of "microneedle" and "vitiligo" or "microneedle" only, respectively. Searched results (research article and review article) regarding the application of microneedles in vitiligo were all included in this review independent of the year of publication. Advancements in microfabrication technology have enabled the precise design of MNs, tailored for delivering both low- and high-molecular-weight biotherapeutics or extracting blood and interstitial fluid (ISF) through the skin. 4,5 The formulation of MNs has garnered considerable interest from academic researchers and pharmaceutical companies, leading to the patenting of diverse MNs designs for transdermal drug delivery. Currently, the patent landscape for MNs is primarily focused on applications in oncology, cosmetics, ophthalmology, diabetes therapy, and vaccination. MNs are primarily classified into five categories: solid, coated, hollow, diss -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal